BioCentury | Sep 21, 2015
Clinical News

Axelopran/oxycodone FDC: Clinical trial data

...mg axelopran/oxycodone FDC was bioequivalent to axelopran and oxycodone co-administered as 2 separate tablets. Additionally, axelopran...
...received either axelopran alone, oxycodone alone, axelopran and oxycodone co-administered as 2 separate tablets or axelopran/oxycodone...
...Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Fixed-dose combination (FDC) of axelopran ( TD-1211...
BioCentury | Jun 12, 2014
Top Story

FDA panel discusses CV outcomes trials in OIC

...the label of Relistor to include OIC in patients with non-cancer pain. Theravance's axelopran ( TD-1211...
BioCentury | Apr 29, 2013
Company News

Theravance infectious, gastrointestinal, pulmonary news

...company will also house Theravance's only marketed drug, antibiotic Vibativ telavancin. Its pipeline will include TD-1211...
BioCentury | Apr 26, 2013
Company News

Theravance splitting up

...company also will house Theravance's only marketed drug, antibiotic Vibativ telavancin. Its pipeline will include TD-1211...
BioCentury | Jul 16, 2012
Finance

Highlights of weekly biotech stock moves

...and to treat COPD in the U.S. Separately, Theravance said 5, 10 and 15 mg TD-1211...
BioCentury | Jul 16, 2012
Clinical News

TD-1211: Phase IIb data

...placebo. Low-dose TD-1211 produced a non-significant increase of 2.7 SBMs on the endpoint (p=0.0739). Additionally, TD-1211...
...response rate was significant with mid- and high-dose TD-1211. Furthermore, 66% of patients receiving high-dose TD-1211...
...plans to begin Phase III testing of TD-1211, but did not disclose a time frame. TD-1211...
BioCentury | Nov 8, 2010
Clinical News

TD-1211: Phase I data

...Phase I trial in 102 healthy volunteers showed that 2-30 mg doses of once-daily oral TD-1211...
...well tolerated. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) has an option to license rights to TD-1211...
...2004 deal (see BioCentury, April 5, 2004). Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-1211...
BioCentury | Nov 8, 2010
Clinical News

TD-1211: Phase II data

...U.S. Phase II trial in 70 patients showed that once-daily 5 and 10 mg oral TD-1211...
...and 3.6 hours for 5 and 10 mg TD-1211, respectively, vs. 28.7 hours for placebo. TD-1211...
...once-daily TD-1211. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) has an option to license rights to TD-1211...
BioCentury | Apr 26, 2010
Clinical News

TD-1211: Phase I started

...Theravance began a double-blind, placebo-controlled, multiple ascending-dose Phase II trial to evaluate oral TD-1211 given once...
...for 14 days in about 50 patients. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-1211...
Items per page:
1 - 9 of 9